Atypical hyperplasia of the breast

Atypical hyperplasia of the breast - risk assessment and management options. NEJM 2015, 372: 78-89.
[preview]

Hartmann, L.C., et al.

http://www.nejm.org/doi/full/10.1056/NEJMsr1407164?af=R&rss=currentIssue

Some benign breast lesions have a greatly increased risk of becoming invasive cancers. Atypical hyperplasia is a common high-risk benign lesion, and measures to prevent its progression to cancer are available but underutilized.

Understanding the factors that influence breast reconstruction decision making in Australian women

Understanding the factors that influence breast reconstruction decision making in Australian women. The Breast, Jan. 2015 [in press]

Somogyi, R.B., et al.

http://www.thebreastonline.com/article/S0960-9776(14)00218-5/abstract?rss=yes


Breast reconstruction is safe and improves quality of life. Despite this, many women do not undergo breast reconstruction and the reasons for this are poorly understood. This study aims to identify the factors that influence a woman's decision whether or not to have breast reconstruction and to better understand their attitudes toward reconstruction.

The breast reconstruction evaluation of acellular dermal matrix as a Sling Trial

The breast reconstruction evaluation of acellular dermal matrix as a Sling Trial: Design and methods of a prospective randomized trial. Plastic and Reconstructive Surgery, Jan 2015, Vol. 135(1), p.20e-28e.

Agarwal, J.P., et al.

http://journals.lww.com/plasreconsurg/Abstract/2015/01000/The_Breast_Reconstruction_Evaluation_of_Acellular.8.aspx

Recent literature has focused on the advantages and disadvantages of using acellular dermal matrix in breast reconstruction. Many of the reported data are from low level-of-evidence studies, leaving many questions incompletely answered. The present randomized trial provides high-level data on the incidence and severity of complications in acellular dermal matrix breast reconstruction between two commonly used types of acellular dermal matrix.

Tamoxifen for prevention of breast cancer

Tamoxifen for prevention of breast cancer: Extended long-term follow-up of the IBIS-I breast cancer prevention trial. The Lancet Oncology, Jan. 2015, Vol. 16(1), p.67-75.

Cuzick, J., et al.

http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71171-4/fulltext?rss=yes

Four previously published randomised clinical trials have shown that tamoxifen can reduce the risk of breast cancer in healthy women at increased risk of breast cancer in the first 10 years of follow-up. We report the long-term follow-up of the IBIS-I trial, in which the participants and investigators remain largely masked to treatment allocation.

Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer

Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. The Lancet Oncology, Jan 2015, Vol. 16(1), p.47-56.

Bartelink, H., et al.

http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71156-8/fulltext?rss=yes

Since the introduction of breast-conserving treatment, various radiation doses after lumpectomy have been used. In a phase 3 randomised controlled trial, we investigated the effect of a radiation boost of 16 Gy on overall survival, local control, and fibrosis for patients with stage I and II breast cancer who underwent breast-conserving treatment compared with patients who received no boost. Here, we present the 20-year follow-up results.

Adjuvant Paclitaxel and Trastuzumab for node-negative, HER-2 positive breast cancer

Adjuvant Paclitaxel and Trustuzumab for node-negative, HER-2 positive breast cancer. NEJM, 2015; 372: 134-141.

Tolaney, S.M., et al.

http://www.nejm.org/doi/full/10.1056/NEJMoa1406281?af=R&rss=currentIssue

No single standard treatment exists for patients with small, node-negative, human epidermal growth factor receptor type 2 (HER2)–positive breast cancers, because most of these patients have been ineligible for the pivotal trials of adjuvant trastuzumab.